ilmscore | Prediction Details
"The company's European business is on track to cross €1 billion in annual revenue by the end of FY26."
By Groww | February 10, 2026 | Pending
From video
3 stocks best mutual funds are buying? 00:13:43 - 00:13:48
Interpreted Prediction
Aurbindo Pharma's European business is expected to exceed €1 billion in annual revenue by the end of FY26.

Prediction Details

Ticker
AUROPHARMA.NS

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.